Hims & Hers FDA Surge: $2.2B Peptide Market Opens for Telehealth
Will the FDA's surprising peptide decision turn Hims & Hers into a multi-billion-dollar powerhouse, or is Wall Street right to stay cautious?
Moderna Flu Vaccine -3.4% After FDA Panel Backs Shot
Can the Moderna Flu Vaccine turn an FDA panel win into a real growth story before Wall Street loses patience?
Hims & Hers Health Forecast Jumps 8% on Analyst Upgrades
Can analyst optimism outweigh FDA peptide uncertainty in the Hims & Hers Health Forecast after an 8% stock surge?
Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote
Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again?
Moderna Restructuring +6.3% as FDA Momentum Builds
Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test?
Moderna Hantavirus +12% Rally: Can The Surge Last?
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story?
Hims & Hers peptide regulation: +10.5% rally tests FDA bet
Is the latest FDA shift on peptides turning Hims & Hers into a long-term growth story or just fueling a speculative spike?